CTD Pharma, a acronym for Current Therapeutic Documents, is a comprehensive submission document used in the pharmaceutical industry to present a unified, global, regulatory application dossiers for new drugs. It serves as the primary reference document for the submission of marketing authorizations in the European Union (EU) and other countries following the International Conference on Harmonisation (ICH) Common Technical Document (CTD) format.

CTD Pharma is not just a filing format but a critical tool driving harmonization in the regulatory process worldwide. It facilitates global submission practices, reducing the time, money, and resources spent on re-creating documents to meet different regulatory authorities' requirements. The ICH CTD first introduced in 2003, replaced a multitude of different national and regional submission formats with a single, common standard.

Key Components of CTD Pharma
The CTD Pharma consists of five interconnected modules, each providing a specific type of information necessary for drug approval:

1. Table Of Contents (TOC)
2. Administrative Information
3. Quality
4. Nonclinical Studies
5. Clinical Studies
Module 1: Table Of Contents

The Table of Contents (TOC) is the first module of the CTD Pharma, serving as a roadmap to the document. It contains a list of the sections in the submission, allowing reviewers to quickly navigate to relevant information. The TOC is structured hierarchically, from modules to sections to paragraphs.
Each entry in the TOC includes the module number, section number (if applicable), the section title, and the starting page number. This level of detail ensures that reviewers can pinpoint specific information easily and quickly.
Module 2: Administrative Information

The second module of the CTD Pharma provides administrative information, such as the drug's proposed brand name, trade name, and the identification of the marketing authorization holder. This module also includes the proposed summary of product characteristics (SmPC) and package leaflet (PL).
This section is crucial for identifying and understanding the basic details of the proposed drug product, including its intended use and the target patient population. For generic applications, a detailed comparison with the reference listed drug is also provided here.
Nonclinical and Clinical Data in CTD Pharma

The remaining modules of the CTD Pharma, Quality, Nonclinical Studies, and Clinical Studies, provide detailed information on the drug substance and product, as well as the results of laboratory, animal, and human clinical studies conducted to demonstrate the safety, efficacy, and quality of the drug.
Each of these modules follows a logical, scientific, and step-by-step approach, ensuring that the reviewers evaluate the data in a rigorous, consistent, and understandable manner.









Module 3: Quality
Module 3 contains information related to the quality of the drug substance and product. This includes manufacturing processes, control procedures, and specifications to ensure the reproducibility and reliability of the product's quality, purity, and potency.
Modules 4 and 5: Nonclinical and Clinical Studies
Modules 4 and 5 present the results of safety and efficacy studies conducted on the drug. Module 4 covers nonclinical data from in vitro and in vivo studies, while Module 5 provides clinical data from human trials.
Each study's materials and methods, results, and discussions are included, along with any other relevant information, such as statistical analyses and safety data. These modules provide the comprehensive evidence needed to support the drug's approval.
The use of CTD Pharma has revolutionized the drug approval process, enabling global regulatory harmonization and facilitating mutual recognition of product approvals among regulatory authorities. This improved efficiency benefits pharmaceutical companies and patients alike, by reducing the time and resources needed for drug development and getting innovative medicines to those who need them.